Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes

Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes Mellitus

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00568074

Enrollment

131

Registered

2007-12-05

Start date

2003-12-16

Completion date

2004-09-02

Last updated

2017-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 2

Brief summary

This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of repaglinide and Glurenorm® and Glucobay® given as the mono-therapy in Chinese subjects being treatment-naive type 2 diabetics.

Interventions

DRUGrepaglinide

DRUGGlurenorm®

DRUGGlucobay®

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

30 Years to No maximum

Healthy volunteers

Inclusion criteria

* Type 2 diabetes * No previous treatment for diabetes * HbA1c: 7.0-12.0%

Exclusion criteria

* Type 1 diabetes * Uncontrolled treated/untreated hypertension * Any condition that the Investigator and/or Sponsor feels would interfere with trial participation or evaluation of results * Pregnancy, breast-feeding, the intention of becoming pregnant or judged to be using inadequate contraceptive measures (adequate contraceptive measures are: sterilisation, intra-uterine device (IUD), oral contraceptives or barrier methods)

Design outcomes

Primary

Measure	Time frame
HbA1c	after 3 months of treatment

Secondary

Measure	Time frame
fasting blood glucose	—
hypoglycaemia episodes	—
adverse events	—

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026